Kodiak Sciences (NASDAQ:KOD – Free Report) had its target price increased by JPMorgan Chase & Co. from $124.00 to $128.00 in a research note published on Thursday morning,Benzinga reports. The brokerage currently has an overweight rating on the stock.
Several other research firms have also issued reports on KOD. Weiss Ratings lowered shares of Kodiak Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, October 6th. Lifesci Capital raised their price target on shares of Kodiak Sciences from $85.00 to $145.00 and gave the company an “outperform” rating in a research report on Monday, September 28th. The Goldman Sachs Group began coverage on shares of Kodiak Sciences in a report on Wednesday, September 30th. They set a “neutral” rating and a $103.00 price target on the stock. Jefferies Financial Group reaffirmed a “buy” rating and issued a $112.00 price objective on shares of Kodiak Sciences in a research report on Monday, September 28th. Finally, HC Wainwright upped their price objective on shares of Kodiak Sciences from $96.00 to $126.00 and gave the stock a “buy” rating in a research report on Monday, October 12th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $117.86.
Read Our Latest Stock Analysis on Kodiak Sciences
Kodiak Sciences Stock Down 0.7%
KOD stock opened at $97.17 on Thursday. The firm has a market capitalization of $6.35 billion, a PE ratio of -23.82 and a beta of 2.02. Kodiak Sciences has a twelve month low of $19.25 and a twelve month high of $112.79. The stock’s 50 day moving average is $83.13 and its 200-day moving average is $47.59.
Kodiak Sciences (NASDAQ:KOD – Get Free Report) last announced its quarterly earnings results on Thursday, November 12th. The company reported ($1.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.06) by $0.01. On average, equities research analysts anticipate that Kodiak Sciences will post -4.05 earnings per share for the current fiscal year.
Insiders Place Their Bets
In other Kodiak Sciences news, Director Bros. Advisors Lp Baker acquired 807,840 shares of Kodiak Sciences stock in a transaction on Monday, September 28th. The stock was purchased at an average price of $72.57 per share, for a total transaction of $58,624,948.80. Following the purchase, the director directly owned 19,121,134 shares of the company’s stock, valued at $1,387,620,694.38. This trade represents a 4.41% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Insiders acquired a total of 2,188,845 shares of company stock valued at $181,326,862 over the last 90 days. 44.40% of the stock is currently owned by insiders.
Institutional Investors Weigh In On Kodiak Sciences
A number of hedge funds have recently made changes to their positions in KOD. Baker BROS. Advisors LP boosted its holdings in shares of Kodiak Sciences by 9.7% in the 3rd quarter. Baker BROS. Advisors LP now owns 21,860,941 shares of the company’s stock worth $2,072,417,000 after buying an additional 1,941,755 shares during the last quarter. BlackRock Inc. purchased a new stake in Kodiak Sciences during the second quarter worth about $161,113,000. Jupiter Topco LLC purchased a new stake in Kodiak Sciences during the second quarter worth about $59,507,000. Janus Henderson Group PLC increased its holdings in Kodiak Sciences by 32.5% during the first quarter. Janus Henderson Group PLC now owns 1,325,457 shares of the company’s stock worth $50,540,000 after buying an additional 325,457 shares during the last quarter. Finally, ICONIQ Capital LLC bought a new stake in Kodiak Sciences in the second quarter worth about $49,345,000. 89.06% of the stock is currently owned by institutional investors.
About Kodiak Sciences
Kodiak Sciences is a clinical-stage biopharmaceutical company focused on developing treatments for retinal and other eye diseases. The company’s research centers on therapies designed to address conditions involving damage to the retina and vision loss. Kodiak’s technology platform combines therapeutic antibodies with a biopolymer to create antibody biopolymer conjugates, which are designed to provide sustained treatment effects. Its development programs have included KSI-301, an investigational therapy targeting vascular endothelial growth factor (VEGF) for retinal diseases.
Further Reading
- Five stocks we like better than Kodiak Sciences
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Kodiak Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kodiak Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
